PSMA PET/CT has emerged as a useful modality for planning the treatment of prostate cancer and is expected to significantly impact the management of prostate cancer due to its high lesion-detection ability, particularly in cases of recurrent prostate cancer. The gene discussed is FOLH1; the disease is Familial prostate cancer.